These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37866024)

  • 1. Utilization of FDA approved treatments for neuromyelitis optica spectrum disorder in clinical practice: A survey study of academic neuroimmunologists.
    Thon JM; Sharkus R; Thakkar R; Hunter K; Siegler JE; Thon OR
    Mult Scler Relat Disord; 2023 Dec; 80():105076. PubMed ID: 37866024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
    Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
    Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
    Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
    Paul F; Marignier R; Palace J; Arrambide G; Asgari N; Bennett JL; Cree BAC; De Sèze J; Fujihara K; Kim HJ; Hornby R; Huda S; Kissani N; Kleiter I; Kuwabara S; Lana-Peixoto M; Law L; Leite MI; Pandit L; Pittock SJ; Quan C; Ramanathan S; Rotstein D; Saiz A; Sato DK; Vaknin-Dembinsky A
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37258412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Nie T; Blair HA
    CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder).
    Ali F; Sharma K; Anjum V; Ali A
    Curr Drug Discov Technol; 2022; 19(1):e140122193419. PubMed ID: 34011260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders.
    Gao Y; Zhang B; Yang J
    Ann Pharmacother; 2021 Sep; 55(9):1167-1171. PubMed ID: 33246373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder.
    Yong HYF; Burton JM
    Curr Neurol Neurosci Rep; 2023 Sep; 23(9):489-506. PubMed ID: 37540387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model.
    Lazzaro C; Mazzanti NA; Rossi S; Parazzini F
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1185-1200. PubMed ID: 37795872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary management challenges in seropositive NMOSD.
    Costello F; Burton JM
    J Neurol; 2022 Oct; 269(10):5674-5681. PubMed ID: 35816205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuromyelitis Optica Spectrum Disorder].
    Misu T
    Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.
    Holmøy T; Høglund RA; Illes Z; Myhr KM; Torkildsen Ø
    J Neurol; 2021 Dec; 268(12):4522-4536. PubMed ID: 33011853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor.
    Meher BR; Mohanty RR; Dash A
    Cureus; 2024 Feb; 16(2):e55100. PubMed ID: 38558672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
    Fujihara K; Kim HJ; Saida T; Misu T; Nagano Y; Totsuka N; Iizuka M; Kido S; Terata R; Okumura K; Hirota S; Cree BAC
    Mult Scler Relat Disord; 2023 Nov; 79():104938. PubMed ID: 37769428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.